- Clinical Trials
- April 2025
- 80 Pages
Global
From €2289EUR$2,500USD£1,945GBP
- Report
- May 2024
- 134 Pages
Global
From €5949EUR$6,499USD£5,056GBP
- Report
- May 2024
- 134 Pages
Global
From €5949EUR$6,499USD£5,056GBP
- Report
- December 2022
- 120 Pages
Global
From €4119EUR$4,500USD£3,501GBP
- Report
- April 2023
- 190 Pages
Global
From €3204EUR$3,500USD£2,723GBP
- Report
- April 2023
- 246 Pages
Global
From €6866EUR$7,500USD£5,835GBP
- Report
- July 2022
- 146 Pages
Global
From €6866EUR$7,500USD£5,835GBP
- Report
- October 2018
- 16 Pages
Global
From €9154EUR$10,000USD£7,780GBP
- Report
- April 2025
- 50 Pages
Global
From €2426EUR$2,650USD£2,062GBP
Bardoxolone is a drug used to treat liver and kidney disorders. It is a synthetic triterpenoid that works by activating the Nrf2 pathway, which helps protect cells from oxidative stress. It is used to treat chronic kidney disease (CKD) and non-alcoholic steatohepatitis (NASH). Bardoxolone has been approved by the US Food and Drug Administration (FDA) for the treatment of CKD in adults with type 2 diabetes and stage 4 CKD.
Bardoxolone is a relatively new drug in the market and is still in the early stages of development. It is being studied for its potential to treat other diseases, such as heart failure, chronic obstructive pulmonary disease, and cancer.
The market for Bardoxolone is expected to grow in the coming years as more research is conducted and more clinical trials are conducted. The drug is expected to be a major player in the treatment of liver and kidney disorders.
Some companies in the Bardoxolone market include Reata Pharmaceuticals, Inc., FibroGen, Inc., and AstraZeneca plc. Show Less Read more
